Advancing Scientific Innovation
First in class drug device combination to treat nuisance bleeding in patients on anticoagulants
According to a recent survey by the National Blood Clot Alliance (https://www.stoptheclot.org/
Bio 54 is developing a novel drug/device combination called BXP154 to treat external bleeding from minor wounds in anticoagulant patients. This is a product with the potential to improve the life experience for patients on anticoagulants, and provides a new exciting opportunity in the treatment market.
Bio 54 is an affiliate company of 501 Ventures, LLC (a life science accelerator)
A Better Solution
Current standard of care for these prolonged bleeding episodes is basic wound care, which can take hours or require a hospital visit.
Hand-held Drug Delivery
Bio 54 is developing a novel, hand-held drug delivery device for patients to stop nuisance bleeding events comfortably at home.
Safe & Effective
There is an unmet need for patients on blood thinners who experience nuisance external bleeding
Medicare and Medicaid anticoagulation claims in 20191
%
Combined Medicare and Medicaid anticoagulation claims increase from 2014 to 20191
Combined Medicare and Medicaid anticoagulation spending in 20191
Emergency department visits resulting from bleeding from oral anticoagulants in 20172
1 Angela Duvalyan, Ambarish Pandey, Muthiah Vaduganathan, Utibe R. Essien, Ethan A. Halm, Gregg C. Fonarow and Andrew Sumarsono. (2021) “Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019.” Journal of the American Heart Association, 10(24). https://www.ahajournals.org/doi/10.1161/JAHA.121.022644
2 Geller AI, Shehab N, Lovegrove MC, Rose KO, Weidle NJ, Goring SK, Budnitz DS. Emergency Visits for Oral Anticoagulant Bleeding external icon J Gen Intern Med 2019 Oct 29.
https://www.cdc.gov/medicationsafety/adverse-drug-events-specific-medicines.html